Categories: News

Arbor Biotechnologies to Present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day

CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced Devyn Smith, Ph.D., Arbor’s Chief Executive Officer, will present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day. The event will be held on Tuesday, May 30, 2023, and will be livestreamed.

The following are specific details regarding Arbor Biotechnologies’ presentation at the conference:

Event: Stifel 2023 Tailoring Genes: Genetic Medicines Day
Date: Tuesday, May 30, 2023
Time: 9:10 a.m. ET
Location: Virtual

A webcast of the Stifel 2023 Tailoring Genes: Genetic Medicines Day presentation will be accessible through the Press Releases page of the Company’s website at www.arbor.bio, with a replay available for 90 days following the event.

About Arbor Biotechnologies®
Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry to date. Founded by Feng Zhang, David Walt, David Scott, and Winston Yan, our proprietary discovery engine is focused on discovering and evolving technologies that enable gene knockout, RT editing, precise excisions and large insertions into endogenous loci. Leveraging our wholly owned nucleases as the chassis for genetic modification, we have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question, with a focus on areas of high unmet need. As Arbor continues to advance its pipeline toward the clinic with an initial focus in liver and CNS disease, the Company has also secured several partnerships around gene editing and ex vivo cell therapy programs to broaden the reach of its novel nuclease technology. For more information, please visit: arbor.bio

Media
Amy Bonanno, Solebury Strategic Communications
abonanno@soleburystrat.com
914-450-0349

Staff

Recent Posts

StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order

TORONTO, ON / ACCESSWIRE / April 5, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero"…

1 hour ago

Theralase(R) Granted Canadian Cancer Vaccine Patent

TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

1 hour ago

Planet 13 Announces Grand Opening Date for DAZED! Lounge at the World’s Largest Dispensary – Designed to Elevate the Cannabis Consumption Experience

LAS VEGAS, NV / ACCESSWIRE / April 5, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH)…

1 hour ago

Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia

Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, April 05, 2024 (GLOBE NEWSWIRE)…

1 hour ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…

1 hour ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway…

1 hour ago